专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007019305A2 NEAR INFRARED MICROBIAL ELIMINATION LASER SYSTEMS (NIMELS) FOR USE WITH MEDICAL DEVICES 审中-公开
标题翻译：用于医疗设备的近红外微波消除激光系统（NIMELS）
公开(公告)号：WO2007019305A2
公开(公告)日：2007-02-15
申请号：PCT/US2006/030434
申请日：2006-08-03
申请人： NOMIR MEDICAL TECHNOLOGIES, INC. , BORNSTEIN, Eric
发明人： BORNSTEIN, Eric
IPC分类号： A61N5/06
CPC分类号： A61N5/06 , A61B90/37 , A61B2018/2211 , A61N5/0601 , A61N2005/063 , A61N2005/067
摘要： Methods, systems, and apparatus for Near Infrared Microbial Elimination Laser Systems (NIMELS) including use with medical devices are disclosed. The medical devices can be situated in vivo. Suitable medical devices include catheters, stents, artificial joints, and the like. NIMELS methods, systems, and apparatus can apply near infrared radiant energy of certain wavelengths and dosimetries capable of impairing biological contaminants without intolerable risks and/or adverse effects to biological moieties other than a targeted biological contaminant associated with traditional approaches described in the art (e.g., loss of viability, or thermolysis). Lasers including diode lasers may be used for one or more light sources. A delivery assembly can be used to deliver the optical radiation produced by the source(s) produced to an application region that can include patient tissue. Exemplary embodiments utilize light in a range of 850nm-900 run and/or 905nm-945nm at suitable NIMELS dosimetries.
摘要翻译：公开了包括与医疗设备一起使用的近红外微生物消除激光系统（NIMELS）的方法，系统和装置。医疗器械可以位于体内。合适的医疗装置包括导管，支架，人造关节等。 NIMELS方法，系统和装置可以应用能够损害生物污染物的某些波长的近红外辐射能量和剂量测定，而不是与本领域中描述的传统方法相关的靶向生物污染物以外的生物部分不具有不可容忍的风险和/或不利影响（例如，活力丧失或热解）。包括二极管激光器的激光器可以用于一个或多个光源。输送组件可以用于将产生的源产生的光辐射递送到可包括患者组织的应用区域。示例性实施例在合适的NIMELS剂量测定中使用在850nm-900nm和/或905nm-945nm范围内的光。

2. 发明申请

WO2007014130A2 NEAR INFRARED MICROBIAL ELIMINATION LASER SYSTEM (NIMELS) 审中-公开
标题翻译：近红外微生物消除激光系统（NIMELS）
公开(公告)号：WO2007014130A2
公开(公告)日：2007-02-01
申请号：PCT/US2006/028616
申请日：2006-07-21
申请人： NOMIR MEDICAL TECHNOLOGIES, INC. , BORNSTEIN, Eric
发明人： BORNSTEIN, Eric
IPC分类号： A61N5/067
CPC分类号： A61N5/06 , A61L2/085 , A61L2202/24 , A61N5/0624 , A61N2005/0659 , A61N2005/067
摘要： Methods, systems, and apparatus for Near Infrared Microbial Elimination Laser Systems (NIMELS) are disclosed that can apply near infrared radiant energy of certain wavelengths and dosimetries capable of impairing biological contaminants, for example fungus, without intolerable risks and/or adverse effects to biological moieties other than a targeted biological contaminant. Lasers including diode lasers may be used as one or more light sources. A delivery assembly can be used to deliver the optical radiation produced by the source(s) produced to an application region that can include patient tissue. A flat top lens can be included to produce a flat top beam distribution. Exemplary embodiments utilize laser light in a near infrared range of 850nm-900nm and/or 905nm-945nm at suitable NIMELS dosimetries. For certain applications, laser light in two spectral ranges including 870 nm and 930 nm, respectively, can be utilized.
摘要翻译：公开了近红外微生物消除激光系统（NIMELS）的方法，系统和设备，其可以应用特定波长的近红外辐射能量和能够损害生物污染物例如真菌的剂量测定法，而不会令人难以忍受对靶生物污染物以外的生物部分的风险和/或不利影响。包括二极管激光器的激光器可以用作一个或多个光源。递送组件可以用于将由生产的源产生的光辐射递送至可以包括患者组织的应用区域。可以包括平顶透镜以产生平顶光束分布。示例性实施例利用在适合的NIMELS剂量测量下在850nm-900nm和/或905nm-945nm的近红外范围内的激光。对于某些应用，可以分别使用两种光谱范围的激光，包括870nm和930nm。

3. 发明申请

WO2003103582A2 REDUCTION OF GELATIN CROSS-LINKING 审中-公开
标题翻译：减少凝胶交联
公开(公告)号：WO2003103582A2
公开(公告)日：2003-12-18
申请号：PCT/US2003/017620
申请日：2003-06-05
申请人： IVAX CORPORATION , IVAX PHARMACEUTICALS s.r.o. , VRANA, Ales
发明人： VRANA, Ales
IPC分类号： A61K
CPC分类号： A61K9/4808 , A61K9/4825 , A61K9/4858 , A61K31/355 , A61K47/183
摘要： The invention relates to compositions and methods for reducing cross-linking in the gelatin shell of gelatin capsules by incorporation of free amino acid into the capsule shell and by inclusion of an ester of carboxylic acid either into the capsule filling, and/or into the capsule shell and/or into the lubrication agent, or in combinations thereof. Described are soft gelatin capsules characterized by improved stability as compared with gelatin capsules that do not contain amino acid in the shell and carboxylic acid ester in the filling, shell or in the lubrication agent, or in combinations thereof.
摘要翻译：本发明涉及通过将游离氨基酸并入胶囊壳中并通过将羧酸酯包含在胶囊填充物中和/或胶囊填充物中而减少明胶胶囊明胶壳中的交联的组合物和方法壳和/或进入润滑剂，或其组合。描述的是与明胶胶囊相比具有改善的稳定性的软明胶胶囊，其在壳中不含有氨基酸，在填充物，壳或润滑剂中的羧酸酯或其组合。

4. 发明申请

WO2003086332A1 ANTIMICROBIAL WASH AND CARRIER SOLUTIONS, AND USES THEREOF 审中-公开
标题翻译：抗菌洗涤和载体解决方案及其用途
公开(公告)号：WO2003086332A1
公开(公告)日：2003-10-23
申请号：PCT/US2003/011300
申请日：2003-04-11
申请人： DVM PHARMACEUTICALS, INC.
发明人： FARNG, Richard, K. , MRHA, Steven
IPC分类号： A61K7/00
CPC分类号： A61K47/14 , A61K9/0012 , A61K9/0014 , A61K47/18 , Y10S424/06 , Y10S514/887
摘要： Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, nonirritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.
摘要翻译：新型洗涤剂和载体溶液理想地适用于局部给药（例如作为洗涤溶液和作为载体溶液）。本文描述的溶液是无毒的，无刺激性的，等渗的，具有非特异性广谱抗微生物性质，并且具有碱性pH。还公开了溶液的无菌制剂及其使用方法。

5. 发明申请

WO2003024458A1 NEUROPROTECTION AFTER TRAUMATIC BRAIN INJURY 审中-公开
标题翻译： TRAUMATIC脑损伤后的神经保护
公开(公告)号：WO2003024458A1
公开(公告)日：2003-03-27
申请号：PCT/US2002/029512
申请日：2002-09-18
申请人： IVAX INSTITUTE FOR DRUG RESEARCH, INC.
发明人： BELAYEV, Ludmila , GINSBERG, Myron, D.
IPC分类号： A61K31/551
CPC分类号： A61K31/551
摘要： The invention provides compositions and methods for treating traumatic brain injury by the administration of a noncompetitive AMPA receptor antagonist. In certain embodiments, the noncompetitive AMPA receptor antagonist is a 2,3-benzodiazepine derivative. Illustrative 2,3-benzodiazepine derivatives useful according to the invention include (R)-7-acetyl-5(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3] benzodiazepine.
摘要翻译：本发明提供了通过施用非竞争性AMPA受体拮抗剂治疗创伤性脑损伤的组合物和方法。在某些实施方案中，非竞争性AMPA受体拮抗剂是2,3-苯并二氮杂衍生物。根据本发明有用的示例性2,3-苯并二氮杂衍生物包括（R）-7-乙酰基-5（4-氨基苯基）-8,9-二氢-8-甲基-7H-1,3-二氧杂环戊烯并[4,5- h] [2,3]苯并二氮杂。

6. 发明申请

WO2008013948A3 TYROSINE PHOSPHORYLATION SITES 审中-公开
公开(公告)号：WO2008013948A3
公开(公告)日：2008-01-31
申请号：PCT/US2007/016927
申请日：2007-07-27
申请人： CELL SIGNALING TECHNOLOGY, INC. , POLAKIEWICZ, Roberto , LEE, Kimberly , FARNSWORTH, Charles , GUO, Ailan , RIKOVA, Klarisa , MORITZ, Albrecht , SPEK, Erik
发明人： POLAKIEWICZ, Roberto , LEE, Kimberly , FARNSWORTH, Charles , GUO, Ailan , RIKOVA, Klarisa , MORITZ, Albrecht , SPEK, Erik
IPC分类号： A61K39/395
摘要： The invention discloses 349 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.

7. 发明申请

WO2007032804A2 NOVEL USES FOR ANTI-IGE THERAPY 审中-公开
标题翻译：新的治疗方法
公开(公告)号：WO2007032804A2
公开(公告)日：2007-03-22
申请号：PCT/US2006/025654
申请日：2006-06-30
申请人： RISK, Clifford
发明人： RISK, Clifford
IPC分类号： A61K39/395
CPC分类号： C07K16/4291 , A61K39/39566 , A61K2039/505 , C07K2317/76 , Y10S424/805 , Y10S424/81 , Y10S530/862 , Y10S530/868
摘要： The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/ with a therapeutically effective amount of an anti-IgE Ênoiety. In accordance with the invention, COFD patients with sn elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found, to be useful ioÊ the treatment of COPD patients regardless of their skin test results arid/or in vitro reactivity to a perennial aeroalleigen. Anti-ÊgE moieties, in accordance With the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal iirunuitoglobulln E (e.g., human imntnnoglQbulin E) such as humanized arrti-IgEy hmuanized murine monoclonal antibody, and/or Qmalizumab.
摘要翻译：本发明提供了治疗具有慢性阻塞性肺疾病（COPD）的哺乳动物的方法，其独立于吸烟状态和哮喘状态/具有治疗有效量的抗IgE不良。根据本发明，具有sn升高的血清IgE水平的COFD患者可受益于所公开的治疗方法。在某些情况下，已经发现本公开的方法可用于治疗COPD患者，而不管其皮肤试验结果和/或体外对多年生无机材料的反应性。和根据本发明的抗-EGE部分包括但不限于选择性结合给定的哺乳动物iirunuitoglobull E E（例如人类免疫球蛋白E）的任何IgG抗体，例如人源化α-IgE抗原鼠单克隆抗体，和/或 Qmalizumab。

8. 发明申请

WO2005087317A1 NEAR INFRARED MICROBIAL ELIMINATION LASER SYSTEM 审中-公开
标题翻译：近红外微波消除激光系统
公开(公告)号：WO2005087317A1
公开(公告)日：2005-09-22
申请号：PCT/US2004/004156
申请日：2004-02-11
申请人： BORNSTEIN, Eric
发明人： BORNSTEIN, Eric
IPC分类号： A61N5/067
CPC分类号： C02F1/30 , A61B90/40 , A61L2/085 , A61L2202/24 , A61N5/0601 , A61N5/062 , A61N2005/0605 , A61N2005/0644 , A61N2005/0645
摘要： Dual wavelength laser energy in the low infrared electromagnetic spectrum destroys bacteria via photo-damage optical interactions through direct selective absorption of the optical energy by intracellular bacterial chromophores. The dual wavelength laser system (22) includes an optical assembly including two distinct diode laser ranges (870 nm diode array and 930 nm diode array) that can be emitted to achieve maximal bacterial elimination.
摘要翻译：双波长激光能量在低红外电磁频谱中通过光损伤光学相互作用通过细胞内细菌发色团直接选择性吸收光能来破坏细菌。双波长激光系统（22）包括光学组件，其包括两个不同的二极管激光器范围（870nm二极管阵列和930nm二极管阵列），其可被发射以实现最大的细菌消除。

9. 发明申请

WO2003050085A1 CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1) 审中-公开
标题翻译： [R-（R *，R *）] - 2-（4-氟苯基）-β，二氢-2-羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基）羰基] ] -1H-吡咯 - 羟基钙盐（2:1）
公开(公告)号：WO2003050085A1
公开(公告)日：2003-06-19
申请号：PCT/US2002/039512
申请日：2002-12-11
申请人： IVAX CORPORATION , IVAX C.R., A.S.
发明人： FAUSTMANN, Jiri , JEGOROV, Alexandr
IPC分类号： C07D207/327
CPC分类号： C07D207/34 , C07D207/337
摘要： Novel crystalline forms of atorvastatin calcium designated Fa and Je which are prepared by crystallization from non-aqueous, non-polar solvents at a temperature above 90°C. The crystalline forms are useful as agents for treating hyperlipidemia and hypercholesterolemia.
摘要翻译：名称为Fa和Je的阿托伐他汀钙的新型结晶形式，其通过在高于90℃的温度下从非水性非极性溶剂中结晶而制备。结晶形式可用作治疗高脂血症和高胆固醇血症的药剂。

10. 发明申请

WO2003020735A1 SACCHARIDE SULFATION METHODS 审中-公开
标题翻译： SACCHARIDE硫化方法
公开(公告)号：WO2003020735A1
公开(公告)日：2003-03-13
申请号：PCT/US2002/027614
申请日：2002-08-30
申请人： IVAX RESEARCH, INC. , SMITH, Gregory, A.
发明人： SMITH, Gregory, A.
IPC分类号： C07H1/00
CPC分类号： C07H1/00 , C07H1/06 , C07H3/00 , C08B37/0063 , C08B37/0075 , C08B37/0078
摘要： The invention relates to methods for the sulfation of saccharides. In particular, the invention relates to methods for the sulfation of low molecular weight saccharides derived from glycosaminoglycans.
摘要翻译：本发明涉及糖的硫酸化方法。特别地，本发明涉及用于硫酸化衍生自糖胺聚糖的低分子量糖的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式